London, UK – Injectable Drug Delivery is an industry focused on two overarching topics the development of the device & the interaction between drug product and device. SAE’s 2024 Injectable Drug Delivery conference brings together a complete big pharma speaker line-up providing technical updates on the relationship between drug product formulation and the device primary packaging, with considerations for formulation strategies, extractables & leachables and toxicological testing of injectable devices.
This conference brings case studies from senior big pharma representatives providing an opportunity to discuss formulation considerations in depth for parenteral packaging, this is the perfect opportunity to benchmark your drug delivery programme and optimise the development of your injectable portfolio.
What will you gain?
Evaluate how devices can be co-developed alongside drug products to foster a collaborative approach to improve biocompatibility and effective toxicological testing
Expand on design strategies for injectable delivery of advanced modalities, including cell and gene therapies, large molecule delivery and sub-zero device requirements
Learn through focused presentations tailored to a technical device development and primary packaging audience, exploring vial material and primary component selection, silicone layer thickness studies and standardisation of primary container formats
Benefit from spotlight sessions focusing on sustainable device materials, offering comprehensive perspectives on material development and selection through to disposal
Learn how major device developers are streamlining product development and CMC practices for effective compliance throughout and post-NDA/MAA approval
For further details about the conference, including registration, please click here.
Conference at a glance
When: May 8-9 2024
Venue: Hilton London Kensington – 179-199 Holland Park Avenue, London, UK